Welcome to our dedicated page for Beyondspring SEC filings (Ticker: BYSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BeyondSpring Inc. (NASDAQ: BYSI) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations as a clinical-stage biopharmaceutical company. This SEC filings page aggregates those disclosures and, with AI-powered summaries, helps investors interpret the information most relevant to BeyondSpring’s oncology pipeline and capital structure.
Core filings include the annual report on Form 10‑K, which contains audited consolidated financial statements, notes on research and development spending, general and administrative expenses, net loss from continuing operations, and the presentation of SEED Therapeutics as discontinued operations. Current reports on Form 8‑K document material events such as quarterly financial results, equity offerings under an effective shelf registration statement, updates on the sale of BeyondSpring’s Series A‑1 preferred shares in SEED Therapeutics, and scheduling of the annual meeting of shareholders.
Investors can also review proxy materials, such as the definitive proxy statement on Schedule 14A, which outlines matters submitted to shareholder vote, including ratification of the independent registered public accounting firm. Additional 8‑K filings describe share purchase agreements, lock-up provisions for investors in registered offerings, and changes in BeyondSpring’s ownership percentage in SEED following new financing rounds.
Stock Titan’s AI tools assist by highlighting key elements in lengthy filings: trends in research and development and general and administrative expenses, cash and cash equivalents, deferred revenue, shareholders’ deficit, and noncontrolling interests. The platform also flags items related to capital raises, registration statements, and governance events. Real-time integration with EDGAR means new 10‑K, 8‑K, S‑3, and proxy filings for BYSI appear quickly, while AI-generated overviews help readers understand how each document fits into BeyondSpring’s broader clinical and financing strategy.
BeyondSpring Inc. reports an expected delay in completing the “Second Closings” of its sale of Series A-1 Preferred Shares of SEED Therapeutics Inc. under previously signed purchase agreements.
The company had agreed to sell an aggregate 8,333,637 SEED Series A-1 Preferred Shares for approximately $35.4 million, or $4.25 per share. As part of this, Winning View Investment Limited, FULL TECH CORPORATE DEVELOPMENT LIMITED and Mapfil Investment Limited are scheduled to buy 1,436,327, 555,576 and 1,111,152 shares, respectively, in the Second Closings.
These Second Closings were originally to occur no later than December 15, 2025, but are now expected to be completed in the first half of 2026, with no assurance against further delays or certainty on the exact timing.
BeyondSpring Inc. entered into a Securities Purchase Agreement with Ray Beauty Group Limited for a registered offering of 800,000 ordinary shares at $2.50 per share. The transaction closed on November 21, 2025, providing gross proceeds of $2.0 million before expenses. The shares were issued off an effective shelf registration statement on Form S-3. The investor agreed to a 60-day lock-up from closing, limiting sales and derivative transactions in the shares without the company’s prior written consent, subject to specified exceptions.
BeyondSpring Inc. (BYSI) is conducting a primary offering of 800,000 ordinary shares to Ray Beauty Group Limited at $2.50 per share, raising an estimated $2 million in net proceeds after expenses. The company plans to use the cash to fund its research and development programs and for general corporate purposes, which may include clinical trial and commercial spending, working capital, debt repayment and potential acquisitions.
Shares outstanding are expected to increase from 40,322,320 to 41,122,320 as of the referenced date, modestly diluting existing holders. As of September 30, 2025, BeyondSpring reported a net tangible book value of $(0.49) per share, which would improve to $(0.43) per share on an as-adjusted basis after the offering, but investors buying in this deal face an immediate dilution of $2.93 per share. The company remains a clinical-stage biopharmaceutical developer centered on its lead oncology asset, Plinabulin, and additional preclinical immune agents.
BeyondSpring Inc. filed its Q3 2025 10‑Q, showing a year‑to‑date swing to positive net income attributable to the company of $1,131, driven by a $6,986 gain on sale of subsidiary interests tied to its SEED Therapeutics divestiture plan. From continuing operations, the company reported a year‑to‑date operating loss of $6,349 as it had no revenue, with research and development at $2,915 and general and administrative at $3,434.
Cash and cash equivalents were $12,483 at September 30, 2025. Net cash used in operating activities was $14,265 year‑to‑date, offset by $15,934 provided by investing activities, including proceeds from maturities of short‑term investments and the SEED transaction. Total assets were $29,484, total liabilities $49,294, and shareholders’ deficit widened to $(19,810), reflecting high deferred revenue balances and noncontrolling interests.
The SEED plan advanced: the first closing on February 19, 2025 sold 1,730,454 Series A‑1 shares for $7,354. A second closing is scheduled no later than December 15, 2025, and a third by December 15, 2026, which would reduce BYSI’s SEED stake to 13.62% upon completion. Shares outstanding were 40,332,320 as of September 30, 2025.
BeyondSpring Inc. (BYSI) furnished a current report to announce it issued a press release with financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference.
The company states the information in this report, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act.
BeyondSpring (BYSI): Decheng Capital–affiliated reporting persons, identified as a director, reported open-market sales of ordinary shares. On 10/16/2025, Fund III sold 85,798 shares at a weighted average price of $1.72 (prices ranged from $1.62 to $1.795). On 10/17/2025, Fund III sold 45,513 shares at a weighted average price of $1.76 (prices ranged from $1.73 to $1.80).
Following these transactions, Fund III reported 1,518,893 shares beneficially owned indirectly. Separate indirect holdings reported were 1,617,409 shares by Fund II and 891,734 shares by the Global Healthcare Fund. The sales were executed across multiple prices, with full trade breakdowns available upon request as noted in the footnotes.
BeyondSpring (BYSI) reported insider transactions by Decheng Capital–affiliated funds. Decheng Capital China Life Sciences USD Fund III, L.P. reported sales of 107,361 ordinary shares on 10/13/2025 at a weighted average price of $1.70 (range $1.69–$1.75), 28,495 shares on 10/14/2025 at $1.65 (range $1.62–$1.70), and 17,960 shares on 10/15/2025 at $1.65 (range $1.60–$1.685). Following these trades, Fund III reported 1,650,204 shares indirectly held. Other reported indirect holdings were 1,617,409 shares by Fund II and 891,734 shares by the Global Healthcare Fund.
Decheng Capital affiliates and Dr. Xiangmin Cui reported insider sales of BeyondSpring Inc. (BYSI) ordinary shares across three trading dates. Fund III sold 7,507 shares on
BeyondSpring Inc. (BYSI): Decheng Capital-affiliated reporting persons disclosed open-market sales of ordinary shares. On 10/03, 600 shares were sold at $1.76 (weighted average range $1.73–$1.79); on 10/06, 17,500 shares at $1.78 (range $1.73–$1.7879); and on 10/07, 2,100 shares at $1.79 (range $1.74–$1.80). The filing is made by more than one reporting person, noted as Director and 10% Owner.
Following these transactions, indirect beneficial holdings were reported as 1,817,896 shares by Decheng Capital China Life Sciences USD Fund III, L.P., 1,617,409 shares by Decheng Capital China Life Sciences USD Fund II, L.P., and 891,734 shares by Decheng Capital Global Healthcare Fund (Master), LP.
Decheng Capital reporting persons, including funds managed by Dr. Xiangmin Cui, disclosed insider sales of 7,665 BeyondSpring Inc. (BYSI) ordinary shares across three days. The filings show 4,464 shares sold on 09/30/2025 at a weighted average price of about $1.81, 2,601 shares sold on 10/01/2025 at about $1.80, and 600 shares sold on 10/02/2025 at about $1.73. After the reported transactions, Decheng Capital China Life Sciences USD Fund III, L.P. is shown as beneficially owning approximately 1,838,096–1,841,297 shares (per line entries), while affiliated funds report holdings of 1,617,409 and 891,734 shares respectively. The footnotes state the prices are weighted averages within disclosed ranges and confirm the reporting chain through GP entities managed by Dr. Cui.
FAQ
What is the current stock price of Beyondspring (BYSI)?
What is the market cap of Beyondspring (BYSI)?
